Insulin-like growth factor binding protein (IGFBP)-6 is unique among IGFBPs for its
IGF-II binding specificity.
IGFBP-6 inhibits growth of a number of
IGF-II-dependent
cancers, including
rhabdomyosarcoma,
neuroblastoma and
colon cancer. Although the major action of
IGFBP-6 appears to be inhibition of
IGF-II actions, a number of studies suggest that it may also have IGF-independent actions. Gene array studies show regulation of
IGFBP-6 in many circumstances that are consistent with antiproliferative actions. However, other studies show the opposite, so that
IGFBP-6 may be acting as a counter-regulator in these situations or it may have other as yet undetermined actions. Both the N-terminal and C-terminal domains of
IGFBP-6 contribute to high affinity IGF binding, and the C-terminal domain appears to confer its
IGF-II specificity. The three-dimensional structure of the C-domain of
IGFBP-6 contains a
thyroglobulin type 1 fold, and the
IGF-II binding site is located in the proximal half of this domain adjacent to the
glycosaminoglycan binding site. Future studies are needed to further delineate the putative IGF-independent actions of
IGFBP-6 and to build on the structural information to enhance our understanding of this
IGFBP. This is particularly significant since
IGFBP-6 provides an attractive basis for
therapy of
IGF-II-dependent
tumors.